Ascentage Pharma (6855) Registration filing summary

Company overview and business model

• Global biopharmaceutical company focused on discovering, developing, and commercializing therapies for hematological malignancies, with operations in China, the US, Australia, and Europe.

• Lead assets are olverembatinib (a next-generation TKI) and lisaftoclax (a Bcl-2 inhibitor), both targeting major blood cancers.

• Eleven completed or ongoing registrational trials, including two FDA-regulated Phase 3 trials.

• Integrated capabilities in R&D, manufacturing, and commercialization, with a 200,000 sq. ft. facility in Suzhou.

• Strategic partnerships with Innovent, Takeda, and major research institutions globally.

Financial performance and metrics

• Revenue for the nine months ended September 30, 2024: RMB876.8 million (US$124.9 million), up 400% year-over-year, mainly due to a US$100 million payment from Takeda and increased product sales.

• Net profit for the six months ended June 30, 2024: RMB162.8 million (US$22.4 million), compared to a net loss of RMB402.3 million for the same period in 2023.

• Net loss for the year ended December 31, 2023: RMB925.7 million (US$127.4 million); accumulated losses as of June 30, 2024: RMB5,202.1 million (US$715.8 million).

• Cash and bank balances as of September 30, 2024: RMB1,479.3 million (US$210.8 million).

• R&D expenses for the nine months ended September 30, 2024: RMB707.1 million (US$100.8 million), up 37% year-over-year.

Use of proceeds and capital allocation

• Net proceeds from the IPO will fund R&D for olverembatinib and lisaftoclax, including registrational and clinical trials and regulatory approvals in multiple countries.

• Additional proceeds will support development of other product candidates, technology platforms, and general corporate purposes.

• Intends to retain most available funds and future earnings to operate and expand the business.